Concentration-dependent differential effects of an epothilone analog on cell cycle and p53 signaling

被引:1
作者
An, Fan [1 ]
Zhao, Wet-Jie [1 ]
Tang, Li [1 ]
Qiu, Rong-Guo [1 ]
机构
[1] Dalian Univ Technol, Res Ctr Mol Med, Dalian 116023, Liaoning, Peoples R China
关键词
p53; epothilone; apoptosis; cellular localization; cell cycle arrest; METASTATIC BREAST-CANCER; II CLINICAL-TRIAL; MULTIDRUG-RESISTANCE MDR; PHASE-II; B ANALOG; IXABEPILONE BMS-247550; MITOTIC ARREST; MECHANISMS; PACLITAXEL; APOPTOSIS;
D O I
10.3892/or.2015.4128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor-suppressor protein p53 is considered to be one of the most important transport hubs of cell signal transduction, playing critical roles in the control of cell cycle arrest, apoptosis and many other processes as a nuclear transcription factor. p53 also acts in the cytoplasm to trigger apoptosis. Paclitaxel and other microtubule inhibitors can inhibit the growth of different types of cancer cells and induce apoptosis which is believed to be p53-independent. In the present study, we demonstrated that UTD1, a genetically engineered epothilone analog and a new microtubule inhibitor, activated p53 as a transcription factor at low concentrations demonstrated by its enhanced transcriptional activity and accumulation of p21, which led to cell cycle arrest. However, at high concentrations of UTD1, p53 was accumulated in the cytoplasm which contributed to induction of apoptosis. These observations indicate that the epothilone analog has differential effects on intracellular signaling and implies that p53 plays different roles in cells exposed to different concentrations of the anticancer agent.
引用
收藏
页码:1361 / 1368
页数:8
相关论文
共 35 条
  • [1] [Anonymous], P AM SOC CLIN ONCOL
  • [2] Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
    Bacus, SS
    Gudkov, AV
    Lowe, M
    Lyass, L
    Yung, Y
    Komarov, AP
    Keyomarsi, K
    Yarden, Y
    Seger, R
    [J]. ONCOGENE, 2001, 20 (02) : 147 - 155
  • [3] Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination
    Bergstralh, Daniel T.
    Ting, Jenny P. -Y.
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 (03) : 166 - 179
  • [4] Epothilones and the next generation of phase III trials for prostate cancer
    Bhandari, MS
    Hussain, M
    [J]. BJU INTERNATIONAL, 2005, 96 (03) : 296 - 302
  • [5] Mitotic arrest and cell - Fate why and how mitotic inhibition of transcription drives mutually exclusive events
    Blagosklonny, Mikhail V.
    [J]. CELL CYCLE, 2007, 6 (01) : 70 - 74
  • [6] Prolonged mitosis versus tetraploid checkpoint - How p53 measures the duration of mitosis
    Blagosklonny, MV
    [J]. CELL CYCLE, 2006, 5 (09) : 971 - 975
  • [7] Chen JG, 2003, CANCER RES, V63, P7891
  • [8] Targeting the microtubules in breast cancer beyond taxanes: The epothilones
    Cortes, Javier
    Baselga, Jose
    [J]. ONCOLOGIST, 2007, 12 (03) : 271 - 280
  • [9] Denduluri N, 2007, J CLIN ONCOL, V25, P3421, DOI 10.1200/JCO.2006.10.0784
  • [10] Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
    Denduluri, Neelima
    Lee, James J.
    Walshe, Janice
    Berman, Arlene W.
    Vatas, Ujala
    Chow, Catherine K.
    Steinberg, Seth M.
    Cox, Michael C.
    Low, Jennifer A.
    Swain, Sandra M.
    [J]. INVESTIGATIONAL NEW DRUGS, 2007, 25 (01) : 63 - 67